With star checkpoint inhibitors like Keytruda and Opdivo now sporting subcutaneous formulations, GSK has struck a deal aimed ...

GSK plc to acquire RAPT Therapeutics Inc. for $58.00 per share, with an estimated upfront investment of $1.9 billion.

GSK has agreed to pay $58 per RAPT share, with an upfront payment of $1.9 billion, that will give it global rights to ...

GSK entered into a definitive agreement to acquire RAPT Therapeutics, including RAPT’s long-acting anti-immunoglobulin E (IgE ...

US-based biotech firm is developing treatment for allergies such as nuts, milk and eggs in children and adults ...

GSK's RAPT Therapeutics acquisition will strengthen the former's immunology pipeline – specifically its offerings for food ...

Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular”), an integrated biopharmaceutical company committed to redefining the retina ...

GSK has agreed to acquire RAPT Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing novel ...

South Korean biotech Alteogen (Kosdaq: 196170) has signed an exclusive license agreement with Tesaro, a unit of GSK (LSE: GSK ...

GSK to acquire California-based biopharma company, RAPT Therapeutics for $2.2 billion: London, UK Tuesday, January 20, 2026, 16:45 Hrs [IST] GSK plc announced that it has entered ...

GSK has agreed to acquire the US biotech RAPT Therapeutics for $2.2bn, marking the latest move by the UK drugmaker to bolster ...

Top financial stories include CK Hutchison discussing selling Three Ireland to Liberty Global, GSK acquiring Rapt ...